omp-305b83
mAbexperimentalMulti-specific
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02298387)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor AANTAGONIST
VEGF
- Delta-like protein 4ANTAGONIST
DLL4
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
- Delta-like protein 4INHIBITOR
DLL4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989984 ↗
Also known as
- omp-305b83
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05453825 | Phase 2 | Aug 5, 2022 | OncXerna Theraputics, Inc. |
| NCT05043402 | Phase 3 | Nov 1, 2021 | OncXerna Theraputics, Inc., University of Oklahoma |
| NCT03030287 | Phase 1 | Dec 1, 2016 | Mereo BioPharma |
| NCT03035253 | Phase 1 | Dec 1, 2016 | Mereo BioPharma |
| NCT02298387 | Phase 1 | Dec 1, 2014 | Mereo BioPharma, University of Michigan |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mereo BioPharma | For profit | 3 | 3 | 1 | 2014 |
| OncXerna Theraputics, Inc. | For profit | 2 | 2 | 2 | 2021 |
| University of Michigan | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Oklahoma | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1